Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
The California biotech faces one last hurdle before potential approval of its double chin injectable ATX-101 when it comes in front of the FDA’s dermatology advisory committee.
The hot field of immuno-oncology once again dominated the deal landscape with tie-ups between Bristol and Five Prime, Tesaro and AntaptysBio, and Medimmune and MD Anderson. Kythera and Bayer parted ways while Sanofi Pasteur teamed up with SK Chemicals.
The biotech buys back rights to its own drug after attaining a more advantageous financial position and successful late-stage results.